• Explore /
  • Poster
  • / Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML).

Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML).

Abstract Poster

Authors

null

Tara L. Lin

University of Kansas Medical Center, Kansas City, KS

Tara L. Lin , Bruno C. Medeiros , Geoffrey L. Uy , Laura Fugal Newell , Ellen K. Ritchie , Robert K. Stuart , Stephen Anthony Strickland , Donna Hogge , Scott R. Solomon , Richard M. Stone , Dale L. Bixby , Jonathan E. Kolitz , Gary J. Schiller , Matthew Joseph Wieduwilt , Daniel H. Ryan , Robert J Ryan , Michael Chiarella , Arthur Chin Louie , Jeffrey E. Lancet , Jorge E. Cortes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT01696084

Citation

J Clin Oncol 36, 2018 (suppl; abstr 7040)

DOI

10.1200/JCO.2018.36.15_suppl.7040

Abstract #

7040

Poster Bd #

100

Abstract Disclosures

Similar Posters

First Author: Geoffrey L. Uy

First Author: Jeffrey E. Lancet

First Author: James K. McCloskey

First Author: Tara L. Lin